THE 10 MUST-DOs FOR AN EFFECTIVE HEALTHCARE INVESTOR PLAN
Robert Uhl, member of the life science team at Westwicke Partners, writes about how to manage a US investor engagement plan in current markets
Healthcare investors, particularly in biotech, have always had a high tolerance for risk. After all, most biotechs are development-stage companies based on high science without any reliable earnings. As everyone knows, market conditions have been tough lately. After a difficult 2016, at the time of writing, only four life science IPOs have priced in the US in 2017 and two companies have withdrawn plans to go public.
Despite this backdrop, investors should still be actively considering the sector because the payoff can be huge.